Document is current

Article History

Received: 9 July 2021

Accepted: 24 January 2022

First Online: 12 March 2022

Declarations

:

: The intervention is targeted at the Trust level, and NHS research ethics approval is not required. Institutional approval was sought from the Health Sciences Research Governance Committee of the University of York; the committee felt that research ethics approval was not necessary for this study (reference no: HSRGC/2018/256/D). HRA approval was sought and obtained (IRAS 238457). Consent for a Trust to participate was obtained from Trust executives as outlined in our protocol paper.

: Not applicable.

: ABS is undertaking a PhD funded by the same grant as this trial.MR receives grants for other works not related to the topic of this trial from industry (Stryker, Zimmer, Heraeus, Depuy, Smith and Nephew, Convatec, 3M Healthcare, Schulke) and charities (The Health Foundation, Orthopaedic Research UK).AK has received consultancy and speaker fees from Vifor pharma and Pharmacosmos. He has received non-financial support from Pharmacosmos in the form of data support for local service development. All of which is outside the submitted work.York Trials Unit has received funding from the British Orthopaedic Association to support the development of randomised controlled trials.ABS, MR, CM, DT, AB and DJT are in receipt of grants from the National Institute for Health Research including a trial evaluating the effectiveness of treatments for MRSANo funding body has had input, involvement or influence in this manuscript, and have not seen the manuscript prior to submission.Full ICMJE disclosures are available for all authors on request.